샘플 요청 목록에 추가
세계의 흑색종 시장에 대해 조사했으며, 시장의 개요와 출시 치료법, 파이프라인 동향, 향후 전망 등을 제공하고 있습니다.
목차 개요
치료 알고리즘
조사 목적
출시 치료법
개요
면역치료
Opdivo/Yervoy(nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
Opdualag(nivolumab/relatlimab; Bristol Myers Squibb)
Keytruda(pembrolizumab; Merck & Co.)
BRAF/MEK 저해제
개요
주요 인사이트 요약
Tafinlar/Mekinist(dabrafenib/trametinib; Novartis)
Cotellic/Zelboraf(cobimetinib/vemurafenib; Roche)
Braftovi/Mektovi(encorafenib/binimetinib; Pfizer)
종양용해성 바이러스/면역 자극제
개요
Imlygic(T-VEC/talimogene laherparepvec, Amgen)
종양 침윤 림프구(TIL) 세포치료
주요 인사이트 요약
Amtagvi(lifileucel; Iovance Biotherapeutics)
파이프라인 요법
면역 체크포인트 저해제
개요
주요 인사이트 요약
BAL/BOT(balstilimab/botensilimab; Agenus)
Libtayo([cemiplimab)]/fianlimab; Regeneron)
Keytruda([pembrolizumab]/vibostolimab; Merck & Co.)
병변내 약제
개요
주요 인사이트 요약
RP1(vsolimogene oderparepvec, Replimune)
Nidlegy(bifikafusp alfa + onfekafusp alfa; Philogen)
CMP 001(vidutolimod; Regeneron)
재조합 면역 자극제
개요
주요 인사이트 요약
IO 102(IDOlong) /IO 103[PD-L1 펩티드 백신], IO Biotech
mRNA-4157(V940[맞춤형 암 백신], Moderna)
차세대 BRAF/MEK 저해제
개요
주요 인사이트 요약
LXH 254(naporafenib, Erasca)
HL-085(tunlametinib, KeChow Pharma)
면역 세포 독성/T 림프구 자극제
개요
주요 인사이트 요약
Kimmtrak(tebentafusp, Immunocore/Medison Pharma)
IMC-F106C(brenetafusp, Immunocore)
히스톤 탈아세틸화 효소(HDAC) 저해제
개요
주요 인사이트 요약
Epidaza/Hiyasta(tucidinostat, HUYA Bioscience International)
중기/초기 단계 파이프라인
주요 인사이트 요약
전문가가 암 면역치료의 유망한 최전선을 강조 : B7-H3, 이중특이성항체, 새로운 조합이 선도
부록
뉴스
KSA
This report provides a comprehensive analysis of the current and future landscape of melanoma therapies. It delves into insights from key opinion leaders (KOLs) across the US, Australia, and Europe, focusing on the evolving roles of established treatments like Opdivo and Yervoy and emerging therapies. Gain an understanding of the latest clinical data, ongoing trials, and the impact of biosimilars on treatment accessibility. This report also explores the challenges and opportunities in personalised treatment strategies, offering a detailed view of how the melanoma treatment paradigm is expected to shift in the coming years.
Key questions answered:
What are the preferred first- and subsequent-line melanoma treatments?
How do current and pipeline therapies compare in efficacy and tolerability?
What must pipeline therapies demonstrate to become the top choice?
How will the use of melanoma therapies change by patient segment and preference?
What efficacy and tolerability must pipeline products show to compete?
Which promising pipeline candidates will impact current market players?
How will melanoma treatment evolve for each therapy line?
Key brands covered in this report:
Amtagvi (lifileucel)
BAL/BOT (balstilimab/botensilimab)
Braftovi/Mektovi (encorafenib/binimetinib)
CMP 001 (vidutolimod)
Cotellic/Zelboraf (cobimetinib/vemurafenib;)
Epidaza/Hiyasta (tucidinostat)
HL-085 (tunlametinib)
IMC-F106C (brenetafusp)
Imlygic (T-VEC/talimogene laherparepvec)
IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine])
Keytruda ([pembrolizumab]/vibostolimab)
Keytruda (pembrolizumab)
Kimmtrak (tebentafusp)
Libtayo ([cemiplimab)]/fianlimab)
LXH 254 (naporafenib)
mRNA-4157 (V940)
Nidlegy (bifikafusp alfa + onfekafusp alfa)
Opdivo/Yervoy (nivolumab/ipilimumab)
Opdualag (nivolumab/relatlimab)
RP1 (vusolimogene oderparepvec)
Tafinlar/Mekinist (dabrafenib/trametinib)
List of Companies:
Amgen
Novartis
Roche
GSK
Regeneron
Pfizer
Merck & Co.
Bristol Myers Squibb
Daiichi Sankyo
MacroGenics
Iovance Biotherapeutics
Astex Pharmaceuticals
Moderna
HUYA Bioscience International
Philogen
Immunocore
ALX Oncology
Agenus
IO Biotech
Medison Pharma
Replimune
KeChow Pharma
Erasca
OncoSec Medical
Table of Contents Executive summary
Treatment algorithm
Research objectives
Marketed therapies
Overview
Immunotherapies
Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
Opdualag (nivolumab/relatlimab; Bristol Myers Squibb)
Keytruda (pembrolizumab; Merck & Co.)
BRAF/MEK inhibitors
Overview
Key insights summary
Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche)
Braftovi/Mektovi (encorafenib/binimetinib; Pfizer)
Oncolytic viruses/immunostimulants
Overview
Imlygic (T-VEC/talimogene laherparepvec; Amgen)
Tumour infiltrating lymphocyte (TIL) cell therapy
Key insights summary
Amtagvi (lifileucel; Iovance Biotherapeutics)
Pipeline therapies
Immune checkpoint inhibitors
Overview
Key insights summary
BAL/BOT (balstilimab/botensilimab; Agenus)
Libtayo ([cemiplimab)]/fianlimab; Regeneron)
Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.)
Intralesional agents
Overview
Key insights summary
RP1 (vusolimogene oderparepvec; Replimune)
Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen)
CMP 001 (vidutolimod; Regeneron)
Recombinant immunostimulants
Overview
Key insights summary
IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine]; IO Biotech)
mRNA-4157 (V940 [personalised cancer vaccine]; Moderna)
Next-generation BRAF/MEK inhibitors
Overview
Key insights summary
LXH 254 (naporafenib; Erasca)
HL-085 (tunlametinib; KeChow Pharma)
Immunologic cytotoxicity/T lymphocyte stimulants
Overview
Key insights summary
Kimmtrak (tebentafusp; Immunocore/Medison Pharma)
IMC-F106C (brenetafusp; Immunocore)
Histone deacetylase (HDAC) inhibitor
Overview
Key insights summary
Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International)
Mid/early-stage pipeline
Key insights summary
Experts highlight promising frontiers in cancer immunotherapy: B7-H3, bispecifics, and novel combinations lead the way
Appendix
KOL details
KOLs from the Australia/USA
KOLs from Europe
News
